CA2284710A1 - Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist - Google Patents

Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist Download PDF

Info

Publication number
CA2284710A1
CA2284710A1 CA002284710A CA2284710A CA2284710A1 CA 2284710 A1 CA2284710 A1 CA 2284710A1 CA 002284710 A CA002284710 A CA 002284710A CA 2284710 A CA2284710 A CA 2284710A CA 2284710 A1 CA2284710 A1 CA 2284710A1
Authority
CA
Canada
Prior art keywords
compound
carboxylic acid
protecting group
formula
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002284710A
Other languages
English (en)
French (fr)
Inventor
Giuseppe Alvaro
Barbara Bertani
Romano Di Fabio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284710A1 publication Critical patent/CA2284710A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002284710A 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist Abandoned CA2284710A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9706294.7A GB9706294D0 (en) 1997-03-26 1997-03-26 Heterocyclic compound
GB9706294.7 1997-03-26
PCT/EP1998/001700 WO1998042673A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Publications (1)

Publication Number Publication Date
CA2284710A1 true CA2284710A1 (en) 1998-10-01

Family

ID=10809909

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284710A Abandoned CA2284710A1 (en) 1997-03-26 1998-03-24 Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist

Country Status (20)

Country Link
EP (1) EP0971896A1 (pt)
JP (1) JP2001518901A (pt)
KR (1) KR20010005567A (pt)
CN (1) CN1257482A (pt)
AP (1) AP9901659A0 (pt)
AU (1) AU731394B2 (pt)
BR (1) BR9808424A (pt)
CA (1) CA2284710A1 (pt)
EA (1) EA199900755A1 (pt)
GB (1) GB9706294D0 (pt)
HU (1) HUP0001661A3 (pt)
ID (1) ID24306A (pt)
IL (1) IL131919A0 (pt)
IS (1) IS5186A (pt)
NO (1) NO994679L (pt)
NZ (1) NZ337793A (pt)
PL (1) PL335865A1 (pt)
TR (1) TR199902315T2 (pt)
WO (1) WO1998042673A1 (pt)
YU (1) YU47699A (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9917822D0 (en) * 1999-07-29 1999-09-29 Imperial College Nmda antagonist
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
DE10306202A1 (de) * 2003-02-13 2004-08-26 Grünenthal GmbH Arzneimittel enthaltend substituierte 2-Aryl-Aminoessigsäure-Verbindungen und/oder substituierte 2-Heteroaryl-Aminoessigsäure-Verbindungen
JP4360891B2 (ja) 2003-12-09 2009-11-11 アルパイン株式会社 放送受信機能を備えた電子装置およびその装置における電子番組ガイドの表示方法
RU2451014C2 (ru) * 2005-07-22 2012-05-20 Мотида Фармасьютикал Ко., Лтд. Новое производное гетероциклиден ацетамида
NZ565080A (en) 2005-07-22 2011-03-31 Mochida Pharm Co Ltd Novel heterocyclidene acetamide derivative
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
RU2020100230A (ru) 2017-06-12 2021-07-13 Глитек Ллс. Лечение депрессии антагонистами nmda и антагонистами d2/5-ht2a или селективными антагонистами 5-нт2a

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0386839B1 (en) * 1989-03-08 1997-01-15 Merck Sharp & Dohme Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5977136A (en) * 1995-09-29 1999-11-02 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds

Also Published As

Publication number Publication date
BR9808424A (pt) 2000-05-23
IS5186A (is) 1999-09-17
WO1998042673A1 (en) 1998-10-01
NO994679D0 (no) 1999-09-24
AP9901659A0 (en) 1999-09-30
AU731394B2 (en) 2001-03-29
EA199900755A1 (ru) 2000-08-28
GB9706294D0 (en) 1997-05-14
TR199902315T2 (xx) 2000-05-22
JP2001518901A (ja) 2001-10-16
NO994679L (no) 1999-11-24
PL335865A1 (en) 2000-05-22
KR20010005567A (ko) 2001-01-15
EP0971896A1 (en) 2000-01-19
IL131919A0 (en) 2001-03-19
HUP0001661A2 (hu) 2000-09-28
ID24306A (id) 2000-07-13
NZ337793A (en) 2001-02-23
HUP0001661A3 (en) 2001-12-28
AU7209498A (en) 1998-10-20
YU47699A (sh) 2001-12-26
CN1257482A (zh) 2000-06-21

Similar Documents

Publication Publication Date Title
US5374648A (en) Indole derivatives and pharmaceutical use thereof
US5686461A (en) Indole derivatives
AP877A (en) Tetrahydroquinoline derivatives as EAA antagonists.
US5919811A (en) 3-Substituted-indole-2-carboxylic acid derivatives as excitatory amino acid antagonists
US5977136A (en) Tetrahydroquinolines as NMDA antagonists
AU731394B2 (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
AU753867B2 (en) Tetrahydroquinoline derivatives as glycine antagonists
US6713491B2 (en) Heterocyclic derivatives
MXPA99008720A (en) Quinoline-2-carboxylic acid derivative and its use as excitatory amino acids antagonist
CZ340599A3 (cs) Derivát kyseliny chinolin-2-karboxylové

Legal Events

Date Code Title Description
FZDE Discontinued